The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Fintel reports that on January 16, 2025, UBS downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Buy ...

Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, ...

REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...

General Douglas MacArthur High School senior Melody Hong has been named one of 300 semifinalists in the 2025 Regeneron ...

UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...